Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8681
Sealed predictions
- CLDN5 in dopamine neurons, braak-0.42 (p 0.262) → +0.14 (p 0.722)receipt 8688
Swarm cases
receipt 8688: CLDN5 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.761, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.761, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.677, n 18). could be the mix.
- skeptic
- leave-one-out range -0.20 to +0.04, sign flips 3; without severely affected donors -0.08 (p 0.761, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.66 (p 0.0030, n 18) vs -0.08 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CLDN5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CLDN5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 2.5e-4)
Receipts
loading the receipts